Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.
Monika Joshi, MD
Advertisement
Articles by Monika Joshi, MD
Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.
Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, discusses a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial carcinoma.
Advertisement
Latest Updated Articles
Dr. Joshi on Durvalumab/RT Combo in Locally Advanced Urothelial CancerPublished: February 28th 2020 | Updated:
Dr. Joshi on Rationale for Durvalumab/RT Combo in Localized Urothelial CarcinomaPublished: April 15th 2020 | Updated:
Dr. Joshi Discusses Durvalumab and Radiation Therapy in Bladder CancerPublished: February 9th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5